Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 9,441 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06345755
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo, Midazolam
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 4:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126
View directory record Official record
Conditions
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Interventions
EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant, Exemestane
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

NCT03633526
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Aurora, Colorado • Chicago, Illinois • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 21, 2026, 4:04 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

NCT06848231
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
YA-101, Placebo
Drug
Lead sponsor
Dasher Neuroscience Inc.
Industry
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

NCT02641353
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast Tablet, Apremilast Oral Suspension
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

NCT05285137
View directory record Official record
Conditions
Healthy
Interventions
CD388 Injection, Saline placebo
Combination Product · Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 21, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional

A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease

NCT01803945
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AVE8112, Placebo
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
35 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 21, 2026, 4:04 AM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

NCT07494045
View directory record Official record
Conditions
CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Interventions
CTAP101
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Pharmacokinetics of a Single Large Dose of Vitamin D3

NCT00473239
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
cholecalciferol.
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 21, 2026, 4:04 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT05002777
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
11
States / cities
Cerritos, California • Glendale, California • Long Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

NCT05203692
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment

NCT00519792
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Omega DUROS device
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of CTP-543 in Healthy Volunteers

NCT03880136
View directory record Official record
Conditions
Healthy
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

NCT00909311
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-450, ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

NCT00694044
View directory record Official record
Conditions
Healthy, Non-Smoking
Interventions
varenicline, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

NCT00698464
View directory record Official record
Conditions
Hepatic Cirrhosis, Alcoholism
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

NCT05467709
View directory record Official record
Conditions
Health Volunteers
Interventions
Midazolam, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 21, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional

AMG 761 in Adults With Asthma

NCT01514981
View directory record Official record
Conditions
Asthma
Interventions
AMG 761, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Denver, Colorado • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765

NCT01820936
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Sequence 1: PCI-32765, Sequence 2: PCI-32765, Sequence 3: PCI-32765, Sequence 4: PCI-32765, Sequence 5: PCI-32765
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

NCT02488044
View directory record Official record
Conditions
Arginase I Deficiency, Hyperargininemia
Interventions
AEB1102
Drug
Lead sponsor
Aeglea Biotherapeutics
Industry
Eligibility
2 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Stanford, California • Gainesville, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 21, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional

BLOOM: Pragmatic Feasibility Trial

NCT07287332
View directory record Official record
Conditions
Sepsis, Infection
Interventions
Up-front individualized dosing algorithm, Usual Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 4:04 AM EDT
Recruiting Phase 1 Interventional

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NCT06293898
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Interventions
BL-M07D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

NCT00002387
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

NCT01366521
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 4:04 AM EDT